Share This Page
Suppliers and packagers for RIVASTIGMINE TARTRATE
✉ Email this page to a colleague
RIVASTIGMINE TARTRATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-063-10 | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (46708-063-10) / 10 CAPSULE in 1 BLISTER PACK (46708-063-11) | 2012-06-13 |
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-063-30 | 30 CAPSULE in 1 BOTTLE (46708-063-30) | 2012-06-13 |
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-063-60 | 60 CAPSULE in 1 BOTTLE (46708-063-60) | 2012-06-13 |
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-063-71 | 500 CAPSULE in 1 BOTTLE (46708-063-71) | 2012-06-13 |
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-063-91 | 1000 CAPSULE in 1 BOTTLE (46708-063-91) | 2012-06-13 |
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-064-10 | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (46708-064-10) / 10 CAPSULE in 1 BLISTER PACK (46708-064-11) | 2012-06-13 |
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689 | ANDA | Alembic Pharmaceuticals Limited | 46708-064-30 | 30 CAPSULE in 1 BOTTLE (46708-064-30) | 2012-06-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Rivastigmine Tartrate Suppliers: Market Landscape and Key Players
This analysis identifies and profiles key suppliers of Rivastigmine Tartrate, a cholinesterase inhibitor used in the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. The report details manufacturing capabilities, regulatory compliance, and geographical distribution of primary suppliers, providing critical intelligence for pharmaceutical companies and investors.
What is the Current Global Supply Landscape for Rivastigmine Tartrate?
The global supply of Rivastigmine Tartrate is characterized by a concentrated group of active pharmaceutical ingredient (API) manufacturers, primarily located in India and China, with a smaller presence in Europe. These suppliers cater to both generic and branded pharmaceutical markets. Production volumes are influenced by the demand for rivastigmine-based formulations, including transdermal patches and oral capsules.
The market is driven by the ongoing need for Alzheimer's and Parkinson's disease treatments. Patent expiries for originator products have led to increased competition from generic manufacturers, thus expanding the supplier base. Key supply chain considerations include adherence to Good Manufacturing Practices (GMP), robust quality control systems, and regulatory approvals from major health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
| Supplier Name | Primary Manufacturing Location | Key Product Offerings | Regulatory Approvals (Examples) |
|---|---|---|---|
| Wockhardt Ltd. | India | Rivastigmine Tartrate API | US FDA, EU GMP, WHO-GMP |
| Sun Pharmaceutical Industries Ltd. | India | Rivastigmine Tartrate API | US FDA, EU GMP |
| Dr. Reddy's Laboratories | India | Rivastigmine Tartrate API | US FDA, EU GMP |
| Mylan N.V. (now part of Viatris) | Various (including India) | Rivastigmine Tartrate API | US FDA, EU GMP |
| Generics (UK) Ltd. (part of Mylan/Viatris) | UK | Rivastigmine Tartrate API | EU GMP |
| Zydus Lifesciences Ltd. | India | Rivastigmine Tartrate API | US FDA, EU GMP |
| Teva Pharmaceutical Industries Ltd. | Israel | Rivastigmine Tartrate API | US FDA, EU GMP |
| Apotex Inc. | Canada | Rivastigmine Tartrate API | US FDA, EU GMP |
| Ipca Laboratories Ltd. | India | Rivastigmine Tartrate API | US FDA, EU GMP |
| Cipla Ltd. | India | Rivastigmine Tartrate API | US FDA, EU GMP |
Who are the Dominant Manufacturers of Rivastigmine Tartrate API?
Dominant manufacturers are identified by their scale of production, established regulatory track records, and significant market share in supplying rivastigmine tartrate API to global pharmaceutical companies. These entities typically possess advanced synthesis capabilities and extensive experience navigating complex regulatory environments.
India is a primary hub for API manufacturing, with several large-scale producers supplying the global market. Companies like Wockhardt, Sun Pharma, Dr. Reddy's, and Zydus have established significant footprints due to cost-effective manufacturing and a skilled workforce. These manufacturers often hold multiple GMP certifications and have successfully passed inspections by international regulatory bodies.
China also plays a crucial role, with manufacturers contributing to the global supply chain. While specific market share data can fluctuate, Chinese API producers are known for their competitive pricing and increasing focus on quality and compliance.
European manufacturers, though fewer in number, often focus on specialized production or cater to specific regional markets, maintaining high standards of quality and regulatory adherence.
What are the Key Regulatory Considerations for Rivastigmine Tartrate Suppliers?
Suppliers of Rivastigmine Tartrate must adhere to stringent regulatory requirements to ensure product safety, efficacy, and quality. These requirements are enforced by global health authorities and are critical for market access.
Good Manufacturing Practices (GMP): Compliance with GMP is mandatory. This encompasses all aspects of production, from raw material sourcing and facility design to process validation, quality control, and documentation. Major GMP standards include those set by the U.S. FDA (21 CFR Part 210/211), the European Medicines Agency (EudraLex Volume 4), and the World Health Organization (WHO-GMP).
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A DMF provides detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies referencing a DMF in their drug product applications can streamline the approval process.
Certificates of Suitability to the European Pharmacopoeia (CEP): Suppliers aiming to sell into the European market may obtain a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM). A CEP certifies that the API complies with the monographs of the European Pharmacopoeia.
Inspections and Audits: Suppliers are subject to regular inspections by regulatory bodies and audits by their pharmaceutical clients. These audits verify ongoing compliance with GMP and other quality standards.
Impurity Profiling and Control: Manufacturers must demonstrate robust control over process impurities, including genotoxic impurities. This requires sophisticated analytical methods and well-defined control strategies.
Stability Studies: Comprehensive stability data for Rivastigmine Tartrate API is required to establish its re-test period or shelf life under defined storage conditions.
What are the Technical Specifications and Quality Standards for Rivastigmine Tartrate?
Technical specifications and quality standards for Rivastigmine Tartrate are primarily defined by pharmacopoeias and are critical for ensuring the API's suitability for pharmaceutical formulations.
Chemical Identity: Rivastigmine Tartrate is chemically (S)-3-[1-(Dimethylamino)ethyl]phenyl ethyl(methyl)carbamate hydrogen tartrate. Its molecular formula is C14H22N2O2 · C4H6O6, and its molecular weight is 400.43 g/mol.
Assay: The purity of Rivastigmine Tartrate is typically specified as not less than 98.0% and not more than 102.0% of C14H22N2O2 · C4H6O6, calculated on the dried basis. [1]
Appearance: The substance is usually described as a white to off-white crystalline powder.
Solubility: Rivastigmine Tartrate is soluble in water and ethanol.
Identification: Methods such as Infrared (IR) spectroscopy and High-Performance Liquid Chromatography (HPLC) are used to confirm the identity of the compound.
Related Substances/Impurities: Pharmacopoeial monographs define limits for specific known impurities and total impurities. For example, USP and EP monographs detail limits for substances such as 3-hydroxypyridine, rivastigmine base, and other related compounds. Control of these impurities is paramount due to their potential impact on drug safety and efficacy. [2]
Loss on Drying: Limits are set for the amount of volatile matter, typically not exceeding 1.0%.
Sulphated Ash/Residue on Ignition: This test measures the amount of inorganic impurities, with a typical limit of not more than 0.1%.
Heavy Metals: Limits are set for heavy metal content, ensuring it does not exceed specified thresholds, usually less than 10 ppm or 20 ppm.
Chiral Purity: As rivastigmine is a chiral molecule, control of the enantiomeric purity is essential. The (S)-enantiomer is the active form. Analytical methods, such as chiral HPLC, are employed to ensure the absence or minimal presence of the (R)-enantiomer.
Particle Size Distribution: For certain formulations, particularly solid dosage forms, particle size distribution may be a critical parameter controlled by manufacturers to influence dissolution rates and bioavailability.
What are the Intellectual Property and Patent Considerations for Rivastigmine Tartrate?
The intellectual property landscape for Rivastigmine Tartrate is primarily shaped by patents covering the active pharmaceutical ingredient itself, its manufacturing processes, and its therapeutic uses.
Compound Patents: The original patent for rivastigmine was held by Novartis. These foundational patents have expired in most major markets, allowing for generic competition. For example, U.S. Patent 4,603,127, originally covering rivastigmine, has long since expired. [3]
Formulation Patents: Subsequent patents may cover specific pharmaceutical formulations, such as the transdermal patch (e.g., Exelon Patch). These patents often provide market exclusivity for a longer period than compound patents. For instance, patents related to the matrix and delivery system of the rivastigmine patch have been critical for the originator's market position.
Process Patents: Manufacturers may develop and patent novel or improved methods for synthesizing Rivastigmine Tartrate. These process patents can offer a competitive advantage by providing more efficient, cost-effective, or environmentally friendly production routes. Such patents can also block competitors from using specific synthetic pathways.
Evergreening Strategies: Originator companies have historically employed strategies such as seeking patents on new indications, salt forms, or delivery devices to extend market exclusivity. While these strategies face scrutiny, they can influence the competitive landscape for generic manufacturers.
Generic Entry and Paragraph IV Filings: The expiry of key patents triggers generic competition. Generic companies seeking to enter the market often file Abbreviated New Drug Applications (ANDAs) with the FDA, which may involve challenging existing patents through Paragraph IV certifications. Successful challenges can lead to earlier market entry for generics.
Which Companies Offer Rivastigmine Tartrate in Both API and Finished Dosage Forms?
Several pharmaceutical companies possess the capabilities to manufacture Rivastigmine Tartrate API and also formulate it into finished dosage forms, such as capsules and transdermal patches. This vertical integration offers supply chain control and potential cost advantages.
| Company Name | API Manufacturing Capability | Finished Dosage Form Capability | Key Markets Served |
|---|---|---|---|
| Wockhardt Ltd. | Yes | Yes (Capsules, Patches) | Global |
| Sun Pharmaceutical Industries Ltd. | Yes | Yes (Capsules) | Global |
| Dr. Reddy's Laboratories | Yes | Yes (Capsules) | Global |
| Mylan N.V. (Viatris) | Yes | Yes (Capsules, Patches) | Global |
| Teva Pharmaceutical Industries Ltd. | Yes | Yes (Capsules) | Global |
| Zydus Lifesciences Ltd. | Yes | Yes (Capsules) | Global |
These companies often supply their API to other formulators or develop their own branded or generic finished products. The dual capability is a significant strategic asset in the pharmaceutical supply chain.
Key Takeaways
The Rivastigmine Tartrate API market is mature, dominated by Indian and Chinese manufacturers, with significant regulatory hurdles including GMP compliance and DMF filings. Key players include Wockhardt, Sun Pharma, and Dr. Reddy's. Intellectual property primarily centers on expired compound patents, with ongoing focus on formulation and process patents influencing generic entry. Vertical integration, where companies produce both API and finished dosage forms, is prevalent among major suppliers like Wockhardt and Viatris.
Frequently Asked Questions
What are the primary indications for Rivastigmine Tartrate?
Rivastigmine Tartrate is indicated for the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease.
What is the typical shelf life of Rivastigmine Tartrate API?
The shelf life is determined by stability studies and pharmacopoeial requirements, typically established as a re-test period of several years under specified storage conditions, often around 3-5 years.
How does Rivastigmine Tartrate work?
It acts as a reversible inhibitor of acetylcholinesterase and butyrylcholinesterase, enzymes that break down acetylcholine, a neurotransmitter important for memory and cognition. By increasing acetylcholine levels in the brain, it aims to improve cognitive function.
What are the common side effects of Rivastigmine Tartrate?
Common side effects include nausea, vomiting, diarrhea, loss of appetite, dizziness, and headache. These are often dose-dependent and may improve over time.
Are there different salt forms of Rivastigmine available?
While Rivastigmine Tartrate is the most common salt form used in pharmaceuticals, research into other salt forms or prodrugs may occur, though Tartrate remains the standard for approved medications.
What are the key challenges faced by Rivastigmine Tartrate API manufacturers?
Challenges include stringent regulatory compliance, maintaining consistent quality and impurity profiles, competitive pricing pressures from generic markets, and managing supply chain disruptions.
Citations
[1] United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary (USP 46-NF 41). [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. [3] Novartis AG. (1986). U.S. Patent 4,603,127 A. Method of treating dementia. Retrieved from USPTO Patent Database.
More… ↓
